Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

BET inhibition synergizes with Golcadomide by suppressing MYC and E2F pathways in diffuse large B-cell lymphoma [ChIP-Seq]

ABSTRACT: Golcadomide is a potential first-in-class Aiolos/Ikaros-degrading CRBN E3 ligase modulator (CELMoD) agent designed for the treatment of non-Hodgkin lymphoma (NHL) including diffuse large B-cell lymphoma (DLBCL). Aiolos and Ikaros are two critical lineage factors in lymphoid development that sustain lymphoma growth through recruitment of transcriptional complexes to enhancers and promotors of target genes. Through an epigenetic compound library screening, we found that BET inhibitors sensitize DLBCL cells to golcadomide. Using phenotypic assays and a multi-omics approach, we found that the combination treatment led to synergistic inhibition of MYC and E2F target genes, induction of p21, and subsequent cell cycle arrest. Genome-wide analysis revealed co-occupancy of Aiolos, Ikaros and BRD4 at the promoters of MYC and other genes involved in proliferation, as well as MYC-activating enhancers.

ORGANISM(S): Homo sapiens

PROVIDER: GSE305380 | GEO | 2026/08/13

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

BET inhibition synergizes with Golcadomide by suppressing MYC and E2F pathways in diffuse large B-cell lymphoma [RNA-Seq]

Project description:Golcadomide is a potential first-in-class Aiolos/Ikaros-degrading CRBN E3 ligase modulator (CELMoD) agent designed for the treatment of non-Hodgkin lymphoma (NHL) including diffuse large B-cell lymphoma (DLBCL). Aiolos and Ikaros are two critical lineage factors in lymphoid development that sustain lymphoma growth through recruitment of transcriptional complexes to enhancers and promotors of target genes. Through an epigenetic compound library screening, we found that BET inhibitors sensitize DLBCL cells to golcadomide. Using phenotypic assays and a multi-omics approach, we found that the combination treatment led to synergistic inhibition of MYC and E2F target genes, induction of p21, and subsequent cell cycle arrest. Genome-wide analysis revealed co-occupancy of Aiolos, Ikaros and BRD4 at the promoters of MYC and other genes involved in proliferation, as well as MYC-activating enhancers.

2026-08-13 | GSE305378 | GEO

BET inhibition synergizes with Golcadomide by suppressing MYC and E2F pathways in diffuse large B-cell lymphoma [ATAC-Seq]

2026-08-13 | GSE305381 | GEO

Golcadomide with CD20 T-cell engager extends survival in lymphoma model by boosting T-cell activation and trafficking

Project description:Despite recent clinical advances in the treatment of diffuse large B-cell lymphoma, relapsed/refractory patients remain an unmet medical need. Immune-based therapies, such as CAR T and T cell bispecific antibodies, redirect T-cells to target antigens expressed on the malignant cells, have demonstrated promising antitumor and clinical activity. However, even with these advanced therapies some patients do not have non-durable responses, potentially due to tumor microenvironment factors such as lack of T-cell infiltration. Golcadomide, a potential first-in-class Aiolos and Ikaros degrading CRBN E3 ligase modulator (CELMoD), has a multifaceted mechanism of action, including direct antitumor effects and T-cell activation. This study demonstrates that through specific degradation of transcription factors, Aiolos and Ikaros, golcadomide enhances T-cell function through increased proliferation and cytokine production. Spatial transcriptomic and multiplex immunofluorescence data revealed that single agent golcadomide treatment enhanced T-cell functions in a syngeneic GEMM lymphoma model, including T-cell activation and trafficking to the TME, suggesting potential synergy with T-cell engagers. In a combination with a CD20xCD3 murine surrogate T-cell engager, golcadomide increased T-cell mediated cytotoxicity against lymphoma cells and extended survival in an aggressive lymphoma GEMM compared to single-agent bispecific treatment. These findings support the clinical rationale for combining these immunotherapeutic modalities to improve outcomes in DLBCL.

2026-08-18 | GSE305825 | GEO

Discovery of golcadomide (CC-99282) as a promising drug candidate for diffuse large B-cell lymphoma (DLBCL)

Project description:Diffuse large B-cell lymphoma (DLBCL) is an aggressive, heterogeneous disease with poor prognosis associated with high-risk molecular features. We report the discovery of golcadomide (CC-99282), a novel cereblon-modulating agent, that induces faster and deeper degradation of hematopoietic transcription factors Ikaros/Aiolos compared with first-generation degraders such as lenalidomide. In vitro, golcadomide induced interferon-stimulated genes, promoted apoptosis, robust antiproliferation, and immunogenic cell death, independent of clinical outcome determinators observed with standard care treatment. In vivo, golcadomide exhibited enhanced antitumor activity, resulting in significant tumor regression and tumor-free animals in lymphoma xenograft models. Pharmacological and CRISPR-based screenings demonstrated that targeting apoptosis, cell cycle progression, NF-kB signaling, and nuclear cytoplasmic transport increased antitumor efficacy of golcadomide. In summary, these data represent the discovery of golcadomide as a promising drug candidate for DLBCL and highlight the rationales for future golcadomide-based combination regimens that could improve clinical outcomes for patients.

2025-10-10 | GSE262641 | GEO

CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL

Project description:Cereblon (CRBN), a substrate receptor of the E3 ubiquitin ligase complex CRL4CRBN, is the target of the immunomodulatory drugs lenalidomide and pomalidomide. Recently, it was demonstrated that binding of these drugs to CRBN promotes the ubiquitination and subsequent degradation of two common substrates, transcription factors Aiolos and Ikaros. Here we report that the pleiotropic pathway modifier CC-122, a new chemical entity termed pleiotropic pathway modifier binds CRBN and promotes degradation of Aiolos and Ikaros in diffuse large B-cell lymphoma (DLBCL) and T cells in vitro, in vivo and in patients, resulting in both cell autonomous as well as immunostimulatory effects. In DLBCL cell lines, CC-122-induced degradation or shRNA mediated knockdown of Aiolos and Ikaros correlates with increased transcription of interferon stimulated genes (ISGs) independent of interferon Î±, Î², Î³ production and/or secretion and results in apoptosis in both ABC and GCB-DLBCL cell lines. Our results provide mechanistic insight into the cell of origin independent anti-lymphoma activity of CC-122, in contrast to the ABC subtype selective activity of lenalidomide. Microarray analysis of the OCI-LY10 activated B-cell diffuse large B-cell lymphoma (ABC-DLBCL) cell line treated with the compound CC-122 for 18 hours

2015-11-26 | E-GEOD-75420 | biostudies-arrayexpress

CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL

Project description:Cereblon (CRBN), a substrate receptor of the E3 ubiquitin ligase complex CRL4CRBN, is the target of the immunomodulatory drugs lenalidomide and pomalidomide. Recently, it was demonstrated that binding of these drugs to CRBN promotes the ubiquitination and subsequent degradation of two common substrates, transcription factors Aiolos and Ikaros. Here we report that the pleiotropic pathway modifier CC-122, a new chemical entity termed pleiotropic pathway modifier binds CRBN and promotes degradation of Aiolos and Ikaros in diffuse large B-cell lymphoma (DLBCL) and T cells in vitro, in vivo and in patients, resulting in both cell autonomous as well as immunostimulatory effects. In DLBCL cell lines, CC-122-induced degradation or shRNA mediated knockdown of Aiolos and Ikaros correlates with increased transcription of interferon stimulated genes (ISGs) independent of interferon α, β, γ production and/or secretion and results in apoptosis in both ABC and GCB-DLBCL cell lines. Our results provide mechanistic insight into the cell of origin independent anti-lymphoma activity of CC-122, in contrast to the ABC subtype selective activity of lenalidomide.

2015-11-26 | GSE75420 | GEO

Interactome of Aiolos/Ikaros Reveals Combination Rationale of Cereblon Modulators with HDAC Inhibitors in DLBCL

Project description:Purpose: Cereblon (CRBN), a substrate receptor of the E3 ubiquitin ligase complex CRL4CRBN, is the target of the small molecules lenalidomide (Len) and avadomide (Ava). Upon binding of the drugs, Aiolos and Ikaros are recruited to the E3 ligase, ubiquitylated and subsequently degraded. In DLBCL cells, Aiolos and Ikaros are direct transcriptional repressors of interferon stimulated genes (ISG) and degradation of these substrates results in increased ISG protein levels resulting in decreased proliferation and apoptosis. Herein, we aimed to uncover the mechanism(s) Aiolos and Ikaros use to repress ISG transcription and provide a mechanistic rationale for a combination strategy enhance cell autonomous activites of CELMoDs. Results: We describe that in DLBCL, the repression of ISG transcription is accomplished in part through recruitment of large transcriptional complexes such as the nucleosome remodeling and deacetylase (NuRD) which modify the chromatin landscape of these promoters. A rational combination approach of Ava with a specific HDAC inhibitor leads to a significant increase in ISG transcription compared to either single agent, and synergistic antiproliferative activity in DLBCL cell lines. Conclusion: Our results provide a novel role for lineage factors Aiolos and Ikaros in DLBCL as well as further insight into the mechanism(s) of Aiolos and Ikaros mediated transcriptional repression and unique therapeutic combination strategies.

2022-07-12 | GSE201324 | GEO

Genome wide mapping of IKAROS binding (ChIP-Seq) in U-2932 cell line.

Project description:We here report the genome-wide binding of IKAROS in diffuse large B-cell lymphoma (DLBCL) cell line U-2932.

2024-07-01 | GSE267437 | GEO

Discovery of golcadomide (CC-99282) as a promising drug candidate for diffuse large B-cell lymphoma (DLBCL)

Project description:Discovery of golcadomide (CC-99282) as a promising drug candidate for diffuse large B-cell lymphoma (DLBCL)

| PRJNA1092687 | ENA

BET inhibition synergizes with Golcadomide by suppressing MYC and E2F pathways in diffuse large B-cell lymphoma

Project description:BET inhibition synergizes with Golcadomide by suppressing MYC and E2F pathways in diffuse large B-cell lymphoma

| PRJNA1305422 | ENA